Navigation Links
Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
Date:2/6/2008

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, planned clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
2. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
3. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
4. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
5. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
7. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
8. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
10. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
11. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015 HUYA Bioscience International (HUYA) today ... the Japan Society of HTLV-1, held this week at ... purpose of the Society is to promote research on ... of medical technology and research related to these fields ... "HUYA is proud to support this prestigious conference," ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... Medicine, recently presented new data on the relationship of genetics and hypertension at ... Congress on Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts ...
(Date:8/26/2015)...  The Diabetes Research Institute (DRI), a Center ... School of Medicine, announced today that the first ... the first time a novel transplant technique for ... Phase I/II study builds upon decades of progress ... first step toward the development of the DRI ...
(Date:8/26/2015)... -- After litigating and negotiating patent infringement claims ... United States patent RE43,651 (the ,651 ... the United States without any admission or concession ... As a result of the parties, settlement, the US District ... dismissed the case without prejudice. Under the ...
Breaking Biology Technology:HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4P2i Settles United States Litigation 2
... TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) ... after consideration of potential strategic and financing alternatives, that ... and its stockholders to liquidate the Company,s assets and ... has unanimously approved a Plan of Liquidation and Dissolution ...
... David Nicholls and Martin Brand collaborate with Seahorse ... workshop and will share their years of experience ... Mass., May 29 Seahorse Bioscience, Inc., the ... based metabolic assays announced their first Cellular Bioenergetics ...
... Zeus Research & Development will be one of the ... invention of new devices in interventional gastroenterologyORANGEBURG, S.C., May ... and material science, announces it has been invited to ... 1, 2009. Zeus presenters Dr. Bruce Anneaux, Ph.D. and ...
Cached Biology Technology:TorreyPines Therapeutics Announces its Board of Directors' Approval of Plan of Liquidation and Dissolution 2TorreyPines Therapeutics Announces its Board of Directors' Approval of Plan of Liquidation and Dissolution 3New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the World's Leading Bioenergetics Researchers 2New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the World's Leading Bioenergetics Researchers 3Zeus to Present at Digestive Disease Week in Chicago 2
(Date:8/11/2015)... -- Today, ZUK announced its Android smartphone Z1, featuring ... revenues in 2015 that relate to sales of FPC1155 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... smartphone manufacturer in China and we ... 155 for Z1 , ...
(Date:8/10/2015)... , August 10, 2015 The ... offers comprehensive analysis of the global border security ... generate revenues of $16.4bn in 2015. Now: Border ... is an example of the business critical issue you need ... read visiongain ,s objective analysis of how this will ...
(Date:8/6/2015)... Germany , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking ... Epson,s Moverio BT-200 see-through head mounted display and on ... unprecedented quality and efficiency is brought to personalized visualization ... the first time, professionals and researchers can integrate gaze, ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... within the immune system could help explain why younger people ... diagnosed with variant CJD are, on average, 28 years old ... as affected by the disease. Research at The Roslin ... within the immune system that attract corrupted proteins known ...
... Our brains, it turns out, are eco-friendly. A study published ... Venkatesh Murthy and Jakob Sorensen reveals that our brains have ... cells generate and propagate nerve impulses, or action potentials, by ... and out of the cells. Re-establishing the ion equilibrium after ...
... DIEGO, Oct. 13 CareFusion Corporation (NYSE: CFN ... announced the launch of the EnVe(TM) ventilator - a ... Weighing only 10 pounds, the EnVe ventilator is 70-80 ... the latest in portable and ventilation technology to help ...
Cached Biology News:Cell study explains why younger people more at risk of vCJD 2CareFusion Launches 10-Pound High-Performance Critical Care Ventilator in the U.S. 2CareFusion Launches 10-Pound High-Performance Critical Care Ventilator in the U.S. 3
Anti-human CD48/BLAST-1, clone MEM102, Monoclonal Antibody...
Raf-1 (C-12)-G...
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... culture supernates and serum. Each kit contains ... fifteen 96-well plates, provided that the following ...
E1A (adenovirus early region 1)...
Biology Products: